Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Elanco Animal Health Incorporated is a global animal health company that develops, manufactures, and markets products to prevent and treat disease in animals, improve animal well-being, and enhance productivity in livestock. The company operates within the animal health and veterinary pharmaceutical industries, serving both companion animal and food-producing animal markets. Elanco’s primary revenue drivers are veterinary therapeutics, vaccines, parasiticides, and nutritional products sold to veterinarians, livestock producers, and distributors.
The company operates through two principal business segments: Pet Health and Farm Animal. Elanco serves veterinarians, pet owners, livestock producers, and integrated food companies, with a strategic focus on science-based innovation and established product brands. Elanco traces its origins to 1954 as part of Eli Lilly and Company and was spun off as an independent publicly traded company in 2018, subsequently expanding its scale and portfolio through acquisitions, most notably the integration of Bayer’s animal health business.
Business Operations
Elanco generates revenue primarily through the sale of prescription and over-the-counter animal health products across its Pet Health and Farm Animal segments. The Pet Health segment includes parasiticides, therapeutics, and vaccines for dogs and cats, while the Farm Animal segment focuses on products for cattle, swine, poultry, and other livestock, including anti-infectives, vaccines, and productivity enhancers. Sales are conducted through direct sales forces, distributors, and veterinary channels.
The company operates manufacturing, research, and commercial facilities across multiple countries and controls proprietary formulations, regulatory approvals, and established product brands. Elanco integrates research and development with global regulatory and commercial capabilities. It operates through numerous wholly owned subsidiaries formed to manage regional operations and legacy acquisitions, including assets integrated from Bayer Animal Health, which significantly expanded Elanco’s product portfolio and international reach.
Strategic Position & Investments
Elanco’s strategic direction emphasizes portfolio optimization, innovation in parasiticides and therapeutics, and margin improvement through operational efficiency. Growth initiatives include lifecycle management of existing brands, selective new product launches, and geographic expansion in higher-growth markets. The company has also focused on deleveraging and cost discipline following major acquisitions.
A cornerstone investment was the acquisition of Bayer Animal Health in 2020, which materially increased Elanco’s scale in both companion animal and livestock markets. Elanco continues to invest in research and development targeting areas such as parasitic resistance, disease prevention, and animal wellness. The company is also involved in emerging areas related to sustainable food production and improved animal care outcomes, aligning product development with evolving regulatory and consumer expectations.
Geographic Footprint
Elanco is headquartered in Greenfield, Indiana, United States, and operates globally across North America, Europe, Asia-Pacific, Latin America, and Africa. The company maintains a significant presence in developed markets, including the United States and Western Europe, which represent a substantial portion of revenue.
Internationally, Elanco has manufacturing sites, research facilities, and commercial operations spanning more than 90 countries. Its broad geographic footprint allows the company to serve multinational customers and adapt product offerings to regional regulatory frameworks, animal health needs, and production systems, supporting both global scale and localized market strategies.
Leadership & Governance
Elanco is led by an executive team with experience in animal health, pharmaceuticals, and global operations. The leadership team emphasizes disciplined capital allocation, scientific innovation, and long-term value creation for shareholders, while maintaining compliance with regulatory and animal welfare standards.
Key executives include:
- Jeffrey N. Simmons – President and Chief Executive Officer
- Todd L. Young – Executive Vice President and Chief Financial Officer
- Gilles Froment – Executive Vice President, International
- Lori McFarling – Executive Vice President, Global Human Resources
- Aaron Schacht – Executive Vice President, Innovation, Regulatory and Business Development
The company operates under a board-governed structure consistent with U.S. public company standards, with oversight of strategy, risk management, and executive compensation.